GeranylacetoneCAS# 3796-70-1 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 3796-70-1 | SDF | Download SDF |
| PubChem ID | 1549778 | Appearance | Liquid |
| Formula | C13H22O | M.Wt | 194.31 |
| Type of Compound | Sesquiterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (5E)-6,10-dimethylundeca-5,9-dien-2-one | ||
| SMILES | CC(=CCCC(=CCCC(=O)C)C)C | ||
| Standard InChIKey | HNZUNIKWNYHEJJ-FMIVXFBMSA-N | ||
| Standard InChI | InChI=1S/C13H22O/c1-11(2)7-5-8-12(3)9-6-10-13(4)14/h7,9H,5-6,8,10H2,1-4H3/b12-9+ | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Geranylacetone is a potent inhibitor of β-secretase (BACE1), it may have potential treatment for Alzheimer's disease. 2. Geranylacetone is a TRPV1 agonist. |
| Targets | TRPV | Calcium Channel | IL Receptor | BACE |
Geranylacetone Dilution Calculator
Geranylacetone Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 5.1464 mL | 25.7321 mL | 51.4642 mL | 102.9283 mL | 128.6604 mL |
| 5 mM | 1.0293 mL | 5.1464 mL | 10.2928 mL | 20.5857 mL | 25.7321 mL |
| 10 mM | 0.5146 mL | 2.5732 mL | 5.1464 mL | 10.2928 mL | 12.866 mL |
| 50 mM | 0.1029 mL | 0.5146 mL | 1.0293 mL | 2.0586 mL | 2.5732 mL |
| 100 mM | 0.0515 mL | 0.2573 mL | 0.5146 mL | 1.0293 mL | 1.2866 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- tenofovir diphosphate
Catalog No.:BCC6447
CAS No.:166403-66-3
- Tenofovir Alafenamide Fumarate
Catalog No.:BCC8067
CAS No.:379270-38-9
- Tenofovir alafenamide
Catalog No.:BCC8066
CAS No.:379270-37-8
- Saracatinib (AZD0530)
Catalog No.:BCC1166
CAS No.:379231-04-6
- Cimifugin
Catalog No.:BCN5433
CAS No.:37921-38-3
- Jolkinolide B
Catalog No.:BCN2391
CAS No.:37905-08-1
- Jolkinolide A
Catalog No.:BCN3771
CAS No.:37905-07-0
- Scarlet 808
Catalog No.:BCC9139
CAS No.:3789-75-1
- Ro 08-2750
Catalog No.:BCC7307
CAS No.:37854-59-4
- Nepodin
Catalog No.:BCN6894
CAS No.:3785-24-8
- Germacrene D
Catalog No.:BCN3851
CAS No.:37839-63-7
- Phaseollidin
Catalog No.:BCN5432
CAS No.:37831-70-2
- LM 22A4
Catalog No.:BCC6239
CAS No.:37988-18-4
- 2-Amino-4'-fluorobenzophenone
Catalog No.:BCC8530
CAS No.:3800-06-4
- Sulfamonomethoxine sodium
Catalog No.:BCC9157
CAS No.:38006-08-5
- Tenovin-1
Catalog No.:BCC2239
CAS No.:380315-80-0
- (+)-columbianetin
Catalog No.:BCN2331
CAS No.:3804-70-4
- NBMPR
Catalog No.:BCC7516
CAS No.:38048-32-7
- alpha-Epoxydihydroartemisinic acid
Catalog No.:BCN5434
CAS No.:380487-65-0
- 187-1, N-WASP inhibitor
Catalog No.:BCC5866
CAS No.:380488-27-7
- DQP 1105
Catalog No.:BCC6205
CAS No.:380560-89-4
- CMPDA
Catalog No.:BCC6151
CAS No.:380607-77-2
- [(pF)Phe4]Nociceptin(1-13)NH2
Catalog No.:BCC5778
CAS No.:380620-88-2
- Pterolactam
Catalog No.:BCN5435
CAS No.:38072-88-7
Modulation of Human Neutrophil Responses by the Essential Oils from Ferula akitschkensis and Their Constituents.[Pubmed:27586050]
J Agric Food Chem. 2016 Sep 28;64(38):7156-70.
Essential oils were obtained by hydrodistillation of the umbels+seeds and stems of Ferula akitschkensis (FAEOu/s and FAEOstm, respectively) and analyzed by gas chromatography and gas chromatography-mass spectrometry. Fifty-two compounds were identified in FAEOu/s; the primary components were sabinene, alpha-pinene, beta-pinene, terpinen-4-ol, eremophilene, and 2-himachalen-7-ol, whereas the primary components of FAEOstm were myristicin and Geranylacetone. FAEOu/s, beta-pinene, sabinene, gamma-terpinene, Geranylacetone, isobornyl acetate, and (E)-2-nonenal stimulated [Ca(2+)]i mobilization in human neutrophils, with the most potent being Geranylacetone (EC50 = 7.6 +/- 1.9 muM) and isobornyl acetate 6.4 +/- 1.7 (EC50 = 7.6 +/- 1.9 muM). In addition, treatment of neutrophils with beta-pinene, sabinene, gamma-terpinene, Geranylacetone, and isobornyl acetate desensitized the cells to N-formyl-Met-Leu-Phe (fMLF)- and interleukin-8 (IL-8)-induced [Ca(2+)]i flux and inhibited fMLF-induced chemotaxis. The effects of beta-pinene, sabinene, gamma-terpinene, Geranylacetone, and isobornyl acetate on neutrophil [Ca(2+)]i flux were inhibited by transient receptor potential (TRP) channel blockers. Furthermore, the most potent compound, Geranylacetone, activated Ca(2+) influx in TRPV1-transfected HEK293 cells. In contrast, myristicin inhibited neutrophil [Ca(2+)]i flux stimulated by fMLF and IL-8 and inhibited capsaicin-induced Ca(2+) influx in TRPV1-transfected HEK293 cells. These findings, as well as pharmacophore modeling of TRP agonists, suggest that Geranylacetone is a TRPV1 agonist, whereas myristicin is a TRPV1 antagonist. Thus, at least part of the medicinal properties of Ferula essential oils may be due to modulatory effects on TRP channels.
Inhibition of beta-Secretase Activity by Monoterpenes, Sesquiterpenes, and C13 Norisoprenoids.[Pubmed:28381772]
J Oleo Sci. 2017 Aug 1;66(8):851-855.
Inhibition of beta-secretase (BACE1) is currently regarded as the leading treatment strategy for Alzheimer's disease. In the present study, we aimed to screen the in vitro inhibitory activity of 80 types of aroma compounds (monoterpenes, sesquiterpenes, and C13 norisoprenoids), including plant-based types, at a 200-muM concentration against a recombinant human BACE1. The results showed that the most potent inhibitor of BACE1 was geranyl acetone followed by (+)-camphor, (-)-fenchone, (+)-fenchone, and (-)-camphor with the half-maximal inhibitory concentration (IC50) values of 51.9 +/- 3.9, 95.9 +/- 11.0, 106.3 +/- 14.9, 117.0 +/- 18.6, and 134.1 +/- 16.4 muM, respectively. Furthermore, the mechanism of inhibition of BACE1 by geranyl acetone was analyzed using Dixon kinetics plus Cornish-Bowden plots, which revealed mixed-type mode. Therefore aroma compounds may be used as potential lead molecules for designing anti-BACE1 agents.
